Geovax Labs (Geovax Labs) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Change In Receivables?

Geovax Labs's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Geovax Labs's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Geovax Labs's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Geovax Labs's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Geovax Labs's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Geovax Labs's liquidation value for the three months ended in Mar. 2024 was $-2.54 Mil.

Geovax Labs Change In Receivables Historical Data

The historical data trend for Geovax Labs's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs Change In Receivables Chart

Geovax Labs Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

0.05

-0.11

0.13

0.05

Geovax Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Geovax Labs Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Geovax Labs (NAS:GOVXW) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Geovax Labs's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Geovax Labs's accounts receivable are only considered to be worth 75% of book value:

Geovax Labs's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.769	-	3.304	+	0.75 * 0	+	0.5 * 0
=	-2.54

Geovax Labs Change In Receivables Related Terms

Thank you for viewing the detailed overview of Geovax Labs's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Geovax Labs (Geovax Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVXW) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

GOVX:USA E8L:Germany

Address

1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080

Website

https://www.geovax.com

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.